🔗 Share this article

Given that America continues making historic adjustments to its vaccination recommendations, a particular individual appears somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on Covid vaccines during the global health crisis and has concentrated on alleged fatalities following COVID-19 immunization in her short time at the FDA.

Scheduled Changes to Childhood Immunization Schedule

Public health authorities had intended to announce radical revisions to the childhood vaccination calendar recently, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would put the US at odds with a large portion of the world with little proof for benefit. The announcement has been postponed until the next year.

Rather than the director of the vaccine center, Høeg is listed to speak at the meeting. She was recently named acting director of the FDA’s CDER, the fifth appointee to run the division this calendar year.

A New Direction at the Regulatory Body

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing certain pediatric immunization guidelines in the US to become more similar to Denmark, a country with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

So far statements, she has continued to focus on vaccines – typically the purview of Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Qualifications

The appointee has little discernible background in pharmaceutical research, approval processes or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“She appears not to have the necessary background” for leading the drug-regulation department, said Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a large organization. She lacks background in industry regulation.”

Past directors of CBER would “grasp legal statutes and the underlying principles of drug development”, said Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who led the center have had.”

CDER has an vast workload at the agency, Woodcock emphasized.

“Many people just focuses on the innovative therapies, but the generic drug division clears a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and other areas, and each of these have to be looked after,” she noted. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial administrative component to the position, which supervises in excess of 5,000 staff members. “It is a enormous administrative position, if you execute it properly,” she added.

Response and Disputed Initiatives

In response to questions about Dr. Høeg's credentials and whether this selection represents more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “concerns rely on flawed presumptions”.

“This background is consistent with the duties of her position,” the representative stated, noting the months Høeg spent counseling the agency head on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a contentious rapid therapy clearance system that reportedly concerned her predecessors. “How are these medications being picked for this voucher program? Who makes the choices?” Howard questioned. “There is a lot of secrecy going on at the FDA right now.”

Overall, he said, “the agency looks to be trending towards laxer oversight of all drugs, aside from shots.”

Public Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if concerning, history, some experts said. She released a analysis using unverified crowd-sourced reports to determine the frequency of myocarditis following COVID-19 vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Among her “policy goals” for the incoming government featured revising regulations for recently developed shots and discontinuing “optional” vaccines, she stated following the vote on a podcast. At the FDA, Høeg has reportedly floated the idea of barring adolescent males from receiving Covid vaccines.

“She’s an all-around dogmatist who begins with her conclusions and reverse-engineers to fit the data in a highly deceptive, fraudulent way,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|